In the BioHarmony Drug Report Database

"Preview" Icon

Evinacumab

Evkeeza (evinacumab) is an antibody pharmaceutical. Evinacumab was first approved as Evkeeza on 2021-02-11. It has been approved in Europe to treat hypercholesterolemia. The pharmaceutical is active against angiopoietin-related protein 3.

 

Trade Name

 

Evkeeza
 

Common Name

 

evinacumab
 

ChEMBL ID

 

CHEMBL3545191
 

Indication

 

hypercholesterolemia
 

Drug Class

 

Monoclonal antibodies: fully human, cardiovascular indications; vinca alkaloids

Image (chem structure or protein)

Evinacumab structure rendering